Where does TearOptix, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), TearOptix, Inc. ranks #30,337 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does TearOptix, Inc. hold?

TearOptix, Inc. holds 9 US utility patents granted between 2021 and 2025, spanning 3 technology areas.

What is TearOptix, Inc.'s Innovation Score?

TearOptix, Inc. has an Innovation Score of 43.8 out of 100 (top 27% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does TearOptix, Inc. focus on?

TearOptix, Inc.'s top technology area is G02C (SPECTACLES; Sunglasses OR Goggles Insofar AS They Have THE Same Features AS SPECTACLES; Contact Lenses) with 6 patents, ranking #101 of 397 assignees active in that subclass. Grants appear in 3 CPC subclasses total.

Is TearOptix, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for TearOptix, Inc..

What does claim depth mean for TearOptix, Inc.'s patents?

TearOptix, Inc.'s patents average 16.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the TearOptix, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

TearOptix, Inc.

USPTO PatentsView assignee record - 9 granted patents across 3 technology areas, recorded in grant years 2021–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: G02C (SPECTACLES; Sunglasses OR Goggles Insofar AS They Have THE Same Features AS SPECTACLES; Contact Lenses).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Tearoptix ranks #30,337 of 49,997 tracked US assignees by granted-patent volume, with 9 patents across 3 technology areas.

#30,337
of 49,997 US assignees by volume: Top 27%
by Innovation Score (43.8/100): 16.2
avg claims per patent

USPTO PatentsView assignee plate

Corpus R30337 · US Corporation #30,337 · 9 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 9 grants
MID-PACK #30,337/49,997
PHOTO-FINISH Tarsus Pharmaceuticals
CPC-NARROW G02C · 3 areas
INNOV-PAR 43.8/100
CLAIMS-RICH 16.2 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2021–2025 · 5y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Tarsus Pharmaceuticals, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Tearoptix’s 43.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.0 pts (18%) Velocity 20.0 pts (46%) Breadth 6.1 pts (14%) Claim depth 9.7 pts (22%)

Qualcomm Incorporated · highest

85
TearOptix · this assignee

44
3D Lighting… · lowest

7

What this shows Tearoptix's Innovation Score is 43.8/100 (top 27% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Tearoptix?

Each dot is one of Tearoptix’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Tearoptix’s own 16.2 claims/patent is at or below the 17.6 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Tearoptix vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Tearoptix's grants concentrate

TearOptix, Inc. is a focused PatentsView assignee: 3 CPC subclasses with 66.7% of grants classified under G02C (SPECTACLES; Sunglasses OR Goggles Insofar AS They Have THE Same Features AS SPECTACLES; Contact Lenses). Peak complete grant year is 2023 (3 grants) versus a trough of 1 in 2021. By volume, Tearoptix sits between Tarsus Pharmaceuticals, Inc. and Tedder Industries LLC.

Tearoptix's three-year grant acceleration

TearOptix, Inc. shows 7 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Tarsus Pharmaceut…

9
Taurus Internatio…

9
Teak Isle Manufac…

9
Teal Drones

9
Tecmed

9
Technip E&C

9
Tecnimede—Socieda…

9
Tedder Industries

9
Tearoptix ◀

9

What this shows TearOptix holds 9 patents at rank #30,369, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near TearOptix

By rank, the assignees closest to #30,369 in granted patent volume.

Leaders in G02C (Spectacles)

Other assignees with the most granted patents in TearOptix's primary technology class.

Tearoptix's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

44 Top 27% higher than 73% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2021–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table

TearOptix, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2021	1	11.1%
2022	1	11.1%
2023	3	33.3%
2024	3	33.3%
2025partial year	1	11.1%

Which technologies does TearOptix, Inc. patent most?

G02C - SPECTACLES; Sunglasses OR Goggles Insofar AS They Have THE Same Features AS SPECTACLES; Contact Lenses 6

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 3

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 3

Top 3 of 3 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

TearOptix, Inc.'s patent record in context - here's where to go next.

TearOptix, Inc.'s lead technology class is G02C (SPECTACLES; Sunglasses OR Goggles Insofar AS They Have THE Same Features AS SPECTACLES; Contact Lenses), 66.7% of its portfolio - see every assignee active in that class. Explore G02C
Ranked #30,337 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare TearOptix, Inc. against Tarsus Pharmaceuticals, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 43.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.